Get started

Financials · TDOC

Teladoc Health Inc. (TDOC) financials

For the twelve months ended Sep 30, 2026, Teladoc Health Inc. reported $2.47B of revenue and -$154.82M of net income.

Revenue, TTM
$2.47B
Revenue growth, YoY
-2.4%
Net income, TTM
-$154.82M
Net margin
-6.3%
Free cash flow, TTM
$261.96M
EPS, diluted, TTM
-$0.86
Cash
$849.91M
P/S
0.66
Market cap
$1.64B
Annual revenue$2.53B
FY2016FY2025
Annual net income-$200.32M
FY2016FY2025
Annual free cash flow$285.46M
FY2016FY2025

TDOC revenue and earnings growth

TDOC revenueQ3 2026$605.10M

Quarter YoY
-3.4%
QoQ
-0.3%
FY YoY
-1.5%
5Y CAGR
+18.3%
10Y CAGR
+41.7%

TDOC revenue was $605.10M in fiscal Q3 2026 (ended Sep 30, 2026), down 3.4% from a year earlier and down 0.3% from the prior quarter. For the full fiscal 2025 it was $2.53B, down 1.5% from fiscal 2024. Compound annual growth was +18.3% over 5 years and +41.7% over 10 years. It rose in 8 of the last 10 fiscal years.

TDOC net incomeQ3 2026-$26.93M

TDOC net income was -$26.93M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$49.51M a year earlier. For the full fiscal 2025 it was -$200.32M, compared with -$1.00B in fiscal 2024.

TDOC EPSQ3 2026-$0.15

TDOC diluted EPS was -$0.15 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.28 a year earlier. For the full fiscal 2025 it was -$1.14, compared with -$5.87 in fiscal 2024.

TDOC free cash flowQ3 2026$105.24M

Quarter YoY
+8.5%
QoQ
+65.1%
FY YoY
+0.9%

TDOC free cash flow was $105.24M in fiscal Q3 2026 (ended Sep 30, 2026), up 8.5% from a year earlier and up 65.1% from the prior quarter. For the full fiscal 2025 it was $285.46M, up 0.9% from fiscal 2024. It rose in 2 of the last 4 fiscal years.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$2.53B$2.57B$2.60B$2.41B$2.03B$1.09B$553.31M$417.91M$233.28M$123.16M
Cost of revenue---$743.99M$650.26M$390.83M$184.47M$128.74M$61.62M$31.97M
Gross profit---$1.66B$1.38B$703.13M$368.84M$289.17M$171.66M$91.19M
Research and development$277.92M$307.27M$348.52M$333.63M$311.88M$164.94M$64.64M$54.37M$34.46M$21.82M
Selling, general and admin$431.89M$435.49M$464.66M$449.86M$438.01M$506.68M$164.46M$116.92M$79.78M$48.57M
Operating income-$262.95M-$1.02B-$248.55M-$13.65B-$265.63M-$506.42M-$80.44M-$70.85M-$75.39M-$62.66M
Interest expense$19.71M$23.80M$22.28M$21.94M$81.14M-----
Pre-tax income-$235.53M-$993.65M-$219.61M-$13.66B-$384.66M-$575.99M-$109.45M-$96.97M-$107.01M-$73.71M
Income tax-$35.21M$7.59M$760.0K-$3.81M$44.14M-$90.86M-$10.59M$118.0K-$225.0K$510.0K
Net income-$200.32M-$1.00B-$220.37M-$13.66B-$428.79M-$485.14M-$98.86M-$97.08M-$106.78M-$74.22M
EPS, basic-$1.14-$5.87-$1.34-$84.60-$2.73-$5.36-$1.38-$1.47-$1.93-$1.75
EPS, diluted-$1.14-$5.87-$1.34-$84.60-$2.73-$5.36-$1.38-$1.47-$1.93-$1.75
Diluted shares176.2M170.6M164.6M161.5M156.9M90.5M71.8M65.8M55.4M42.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$781.08M$1.30B$1.12B$918.18M$893.48M$733.32M$514.35M$423.99M$42.82M$50.02M
Receivables$192.83M$214.15M$217.42M$210.55M$168.96M$169.28M$56.95M$43.57M$27.09M$13.81M
Inventory$38.20M$38.14M$29.51M$56.34M$73.08M$56.50M$0---
Current assets$1.12B$1.66B$1.49B$1.32B$1.23B$1.06B$588.00M$532.74M$156.24M$82.72M
Goodwill$283.19M$283.19M$1.07B$1.07B$14.50B$14.58B$746.08M$737.20M$498.52M$188.18M
Total assets$2.86B$3.52B$4.39B$4.35B$17.73B$17.76B$1.60B$1.53B$824.39M$303.67M
Current liabilities$404.74M$941.53M$420.62M$399.77M$331.01M$332.65M$90.18M$62.44M$40.33M$21.07M
Short-term debt----$0$42.56M$0--$2.00M
Long-term debt---------$42.42M
Total debt---------$44.42M
Total liabilities$1.47B$2.03B$2.07B-------
Shareholders' equity$1.39B$1.49B$2.33B$2.31B$16.05B$15.88B$1.01B$1.01B$558.90M$230.87M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$294.36M$293.68M$350.02M$189.29M$193.99M-$53.51M$29.87M-$4.86M-$34.44M-$51.88M
Capital expenditures$8.89M$10.79M$11.46M$16.48M$8.53M$4.02M$3.51M$4.01M$2.63M$2.11M
Free cash flow$285.46M$282.89M$338.56M$172.81M$185.46M-$57.53M$26.36M-$8.87M-$37.07M-$53.98M
Investing cash flow-$266.00M-$124.05M-$156.35M-$167.74M-$72.98M-$590.98M$25.01M-$257.50M-$448.38M$26.15M
Financing cash flow-$551.65M$8.31M$10.85M$6.50M$40.95M$859.14M$35.09M$645.61M$475.43M$20.68M
Stock-based compensation$80.41M$145.95M$201.55M$217.85M$302.59M$475.53M$66.70M$43.77M$30.60M$7.72M
Depreciation and amortization---$256.03M$204.24M$69.50M$38.95M$35.60M$19.09M$8.27M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-1.5%-1.3%8.1%18.4%85.8%97.7%32.4%79.1%89.4%59.2%
Gross margin---69.1%68.0%64.3%66.7%69.2%73.6%74.0%
Operating margin-10.4%-39.7%-9.6%-567.3%-13.1%-46.3%-14.5%-17.0%-32.3%-50.9%
Net margin-7.9%-39.0%-8.5%-567.5%-21.1%-44.3%-17.9%-23.2%-45.8%-60.3%
Free cash flow margin11.3%11.0%13.0%7.2%9.1%-5.3%4.8%-2.1%-15.9%-43.8%
Return on equity-14.5%-67.1%-9.5%-591.9%-2.7%-3.1%-9.7%-9.6%-19.1%-32.1%
Return on assets-7.0%-28.5%-5.0%-314.3%-2.4%-2.7%-6.2%-6.4%-13.0%-24.4%
Current ratio2.771.773.543.293.703.196.528.533.873.93
Debt to equity---------0.19

Source: XBRL data Teladoc Health Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TDOC peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TDOC$2.47B-2.4%-$154.82M-6.3%$1.64B
HIMS$2.87B+29.8%-$190.84M-6.7%$5.35B
LFMD$164.70M+3.8%$201.0K0.1%$101.2M
UNH$449.66B+3.3%$15.88B3.5%$356.28B
HNGE$800.82M+49.9%$168.31M21.0%$9.86B

TDOC FAQ

8 questions
  • What is TDOC revenue?
    Teladoc Health Inc. (TDOC) reported $2.47B of revenue for the twelve months ended Sep 30, 2026. That is down 2.4% from the year before. Revenue for fiscal 2025 was $2.53B.
  • Is TDOC profitable?
    No. Teladoc Health Inc. reported a net loss of $154.82M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does TDOC have?
    Teladoc Health Inc. reported $849.91M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is TDOC revenue growing?
    Teladoc Health Inc.'s revenue changed -1.5% in fiscal 2025, to $2.53B. Its compound annual growth rate was +18.3% over 5 years and +41.7% over 10 years.
  • What is TDOC free cash flow?
    Teladoc Health Inc. generated $261.96M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $268.38M less capital expenditures.
  • What is TDOC earnings per share?
    Diluted earnings per share were -$0.86 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did TDOC last report financial results?
    The latest statements here come from Teladoc Health Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
  • Where does this TDOC financial data come from?
    Quantisnow builds these statements from the structured XBRL data Teladoc Health Inc. files with the SEC. It is provided for information only and is not investment advice.